Understanding genetic factors behind immune-related side effects of cancer treatments
Assessment of germline variants associated with immune-related adverse events following immune checkpoint inhibitors
This study is looking at how certain genes might affect the side effects that cancer patients experience when they receive immune therapy, with the hope of making these treatments safer and more effective for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10942344 on NIH RePORTER |
What this research studies
This research investigates the genetic variants that may contribute to immune-related adverse events (irAEs) experienced by patients undergoing treatment with immune checkpoint inhibitors (ICIs) for cancer. By analyzing data from over 13,000 patients, the study aims to identify specific genetic markers that can predict the likelihood and severity of these side effects. The goal is to enhance the safety and effectiveness of immunotherapy by distinguishing between beneficial immune responses and harmful side effects. This comprehensive approach combines genetic analysis with clinical data to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include cancer patients who are receiving or have received immune checkpoint inhibitors and may be at risk for immune-related adverse events.
Not a fit: Patients who are not undergoing treatment with immune checkpoint inhibitors or those with conditions unrelated to cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to personalized treatment plans that minimize adverse effects while maximizing the effectiveness of cancer immunotherapy.
How similar studies have performed: Previous research has shown promising results in identifying genetic factors associated with immune-related adverse events, indicating that this approach has potential for success.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Choueiri, Toni — Dana-Farber Cancer Inst
- Study coordinator: Choueiri, Toni
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.